Phathom Pharmaceuticals CFO Molly Henderson sells $16,739 in stock

PRINCETON, N.J.—Molly Henderson, Chief Financial Officer and Chief Business Officer of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), recently sold a portion of her holdings in the company. According to a filing with the Securities and Exchange Commission, Henderson sold 3,678 shares of common stock on April 7, 2025, at a weighted average price of approximately $4.55 per share, totaling about $16,739. The transaction comes as the stock trades near its 52-week low of $4.07, having declined over 70% in the past six months, according to InvestingPro data.

The transaction was conducted to satisfy tax withholding obligations upon the settlement of restricted stock units. Following this sale, Henderson retains direct ownership of 89,868 shares of Phathom Pharmaceuticals' common stock. Additionally, she holds 1,911.27 shares indirectly through a 401(k) plan. InvestingPro analysis suggests the stock is currently undervalued, with analysts setting price targets ranging from $12 to $28.

Phathom Pharmaceuticals, based in Florham Park, New Jersey, is involved in the development of pharmaceutical preparations. The company's shares are traded on the NASDAQ under the ticker symbol PHAT. While the company maintains strong liquidity with a current ratio of 4.2, InvestingPro data reveals several additional key metrics and insights available in their comprehensive Pro Research Report.

In other recent news, Phathom Pharmaceuticals has appointed Steven Basta as its new CEO, succeeding Terrie Curran, who resigned for personal reasons. Basta brings extensive leadership experience from previous roles, including CEO positions at SaNOtize and Mahana Therapeutics. Additionally, the company has launched the 2025 Employment Inducement Incentive Award Plan, reserving 2,500,000 shares for equity awards. In analyst updates, Jefferies revised Phathom Pharmaceuticals' price target to $13, maintaining a Buy recommendation, while H.C. Wainwright reaffirmed a Buy rating with a $28 target, emphasizing the commercial growth of VOQUEZNA™. The company's GERD treatment, VOQUEZNA™, has seen significant adoption, with prescriptions rising by approximately 110% to over 300,000. Phathom Pharmaceuticals also partnered with Kenan Thompson to promote the GERD IS NO JOKE campaign, highlighting VOQUEZNA™ as a treatment option. These developments reflect strategic moves to enhance Phathom Pharmaceuticals' market presence and product adoption.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.